GSK's Virtual-Proof-of-Concept Unit in Tune with Lilly's Chorus
Executive Summary
Many readers will have heard of Eli Lilly's Chorus initiative, designed to drive compounds through to proof-of-concept as cheaply and quickly as possible. A less well-publicized but similar discovery-on-a-budget initiative is GlaxoSmithKline's VPoC--virtual-proof-of-concept--unit.You may also be interested in...
Institutionalizing Externalization At Big Pharma – The Third Leg
The pharmaceutical industry has a hard time saying goodbye to strategic assets. In fact, it’s much more adept at welcoming new ones: diversification – either geographic or into areas beyond pure-play pharmaceuticals – has become commonplace. But pharma needs to overcome its entrenched resistance to asset externalization, which should become a critical third leg in its attempts to build long-term shareholder value. Strategic, almost biotech-like externalization strategies should move from a peripheral to a core part of pharma’s activities. Why haven’t they already been embraced?
Lilly Tries to Buy Time
GSK Tries to Mimic Real-World Biotech
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: